glp 1 drugs heart failure GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes GLP-1 Agonists in Cardiovascular Diseases:
Description
Peters V, Tigchelaar-Feenstra EF, Imhann F, Dekens JAM, Swertz MA, Franke LH, et al
Sharing injection devices can transmit infections or diseases
Cardiovascular disease and risk management: standards of care in diabetes-2023
We strive to optimize the benefits of GLP-1 medications, including their potential cardiovascular advantages, to enhance the overall well-being of our patients
Experimental and therapeutic medicine
Nomenclature of hepatic anatomy and resections: A review of the Brisbane 2000 system
